Nanotechnology for fighting cancer

The National Cancer Institute (NCI) announced today at a media briefing a new $144.3 million, five-year initiative to develop and apply nanotechnology to cancer. Nanotechnology, the development and engineering of devices so small that they are measured on a molecular scale, has already demonstrated promising results in cancer research and treatment

"Nanotechnology has the potential to radically increase our options for prevention, diagnosis, and treatment of cancer," said Andrew von Eschenbach, M.D., director of the National Cancer Institute. "NCI's commitment to this cancer initiative comes at a critical time. Nanotechnology supports and expands the scientific advances in genomics and proteomics and builds on our understanding of the molecular underpinnings of cancer. These are the pillars which will support progress in cancer."

To carry out this initiative, the NCI, part of the National Institutes of Health, is forming the NCI Alliance for Nanotechnology in Cancer, a comprehensive, integrated initiative encompassing researchers, clinicians, and public and private organizations that have joined forces to develop and translate cancer-related nanotechnology research into clinical practice.

"The Alliance lays out a process to safely accelerate the application of nanotechnology to cancer research," said NCI Deputy Director Anna Barker, Ph.D. "Central to this initiative will be multidisciplinary partnerships involving physicists, biologists, clinicians, engineers, and other experts that can translate knowledge on cancer and nanotechnology into clinically useful products."

The new NCI Alliance for Nanotechnology in Cancer is one of the first steps in implementing the Cancer Nanotechnology Plan, which was developed over the past 18 months with the input of a broad cross-section of the cancer research and clinical oncology communities. The NCI Alliance consists of four major program activities:

• Centers of Cancer Nanotechnology Excellence (CCNEs): The primary goal of the CCNEs is to integrate nanotechnology development into basic and applied cancer research. Each center will be affiliated with a NCI Comprehensive Cancer Center, university, or research center of engineering and physical science. By leveraging existing NCI resources, these centers will bridge gaps in the development pipeline from materials discovery to preclinical testing.

• Multidisciplinary research teams: Given the multidisciplinary nature of nanotechnology research, investigators with basic science and clinical backgrounds will require training to optimize the development and translation of nanotechnologies toward clinical oncology applications. The NCI will initially use existing career development mechanisms to direct talent to this area, create incentives for cross-disciplinary research, and foster collaboration through training.

• Nanotechnology platforms for cancer research: Over the next five years, investigator-initiated and directed project research will be supported in six key programmatic areas: molecular imaging and early detection, in vivo imaging, reporters of efficacy (e.g., real-time assessment of treatment), multifunctional therapeutics, prevention and control, and research enablers (opening new pathways for research).

• Nanotechnology Characterization Laboratory (NCL): The NCL will perform and standardize the pre-clinical characterization of nanomaterials developed by researchers from academia, government, and industry. The NCL will serve as a national resource and knowledge base for cancer researchers, and facilitate the accelerated regulatory review and translation of nanomaterials and devices into the clinical realm.

The NCI recently signed a memorandum of understanding and an interagency agreement with the National Institute of Standards and Technology to partner with the NCI in this characterization and standardization effort. The NCI will also be working to expand collaborations with the U.S. Food and Drug Administration (FDA) to help define the critical pathway for nanotechnologies to reach the clinic.

Among the key components of the Cancer Nanotechnology Plan are milestones to measure success over two time periods. Within the first three years, the plan calls for acceleration of projects that hold promise for near-term clinical application. After three years, the Alliance will focus on developing solutions to address more difficult technological and biological problems that have the potential to impact detection and treatment.

"We are already seeing how nanotechnology is transforming our ability to translate research advances into clinical advances," said Samuel Wickline, M.D., Professor of Medicine, Physics and Biomedical Engineering at Washington University, St. Louis, Mo., and NCI grantee for nanotechnology research. "The possibilities are enormous for finding very small cancers far earlier than ever before and treating them with powerful drugs at the tumor site alone, while at the same time reducing any harmful side effects. This initiative will allow us to explore using this technology to its full potential."

Recent advances in cancer treatment involving nanotechnology include:

Liposomes, the "first generation" of nanoscale drug delivery devices, were developed to deliver anticancer therapeutics directly at tumors. Specifically, liposomal doxorubicin is being used to treat certain forms of cancer, while liposomal amphotericin B treats fungal infections often associated with aggressive anticancer treatments.

Recently, a nanoparticulate formulation of the well-known anticancer compound taxol was submitted to the FDA as a new treatment for advanced-stage breast cancer.

Other clinical applications of nanotechnology have focused on identifying cancer in its earliest stages, visualizing development of the disease, delivering improved therapy to increase the effectiveness and reduce side effects of drugs, and capturing early signals of drug efficacy.

Related stories:

Study Details How Platinum Nanocages 'Cook' Cancer Cells
Platinum-based anticancer agents have a long history as proven therapeutic agents, but their toxicity and short lifetime in the body and the ability of tumors to develop resistance to these drugs limit the ultimate utility of these agents.
Dual-Mode Nanoparticles Image Tumors Using MRI and PET
Medical imaging represents one of the most used and useful procedures in the oncologist’s diagnostic toolkit, even though each of the most useful techniques—magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning—has its own set of limitations.
Chemists Create Cancer-Detecting Nanoparticles
Magnetic resonance imaging (MRI) can be a doctor’s best friend for detecting a tumor in the body without resorting to surgery. MRI scans use pulses of magnetic waves and gauge the return signals to identify different types of tissue in the body, distinguishing bone from muscle, fluids from solids, and so on.
Overcoming Drug Resistance—Nanoparticles Trigger Built-In Cell-Death Signal
One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.
Mass-Producing Tunable Magnetic Nanoparticles
Taking a cue from the semiconductor industry, a team of investigators at Stanford University has developed a method of producing unlimited quantities of highly magnetic nanoparticles suitable for use as magnetic resonance tumor imaging agents.
Nanoparticles Provide Detailed View Inside Living Animals
Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford CCNE) has shown that it can produce whole-body images in small animals that can reveal the location of tumors and track how these nanoparticles traffic through the body.
Nanosize Rods Light Up Pancreatic Cancer Cells
Quantum dots have shown promise as ultrabright contrast agents for use in a variety of cancer imaging studies. Now, a team of investigators at the Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer Platform Partnership, headed by Paras Prasad, Ph.D., of the State University of New York at Buffalo, has shown that quantum rods may perform even better than their spherical cousins.
New Nanoparticles for Targeting Tumors
As a wide variety of nanoparticles continue to demonstrate their ability to improve the delivery of imaging agents and drugs to tumors, nanoparticle researchers have turned their attention to the challenge of systematically determining how a given nanoparticle’s physical and chemical characteristics affect its ability to target tumors. Such data could provide drug developers with guidelines to help them select the most effective type of nanoparticle for a given therapeutic or imaging application.

News discussion:

Nanotechnology news